OVID — Ovid Therapeutics Share News
0.000.00%
Last trade - 00:00- $462.86m
- $345.64m
- $7.25m
Brief: Ovid Therapeutics Will Reduce Its Workforce By 17 People
U.S. RESEARCH ROUNDUP-Aerovate Therapeutics, Boeing, Wingstop
U.S. RESEARCH ROUNDUP-Aerovate Therapeutics, Boeing, Wingstop
U.S. STOCKS ON THE MOVE-Broadcom, Xponential Fitness, Northfield Bancorp
U.S. STOCKS ON THE MOVE-Broadcom, Xponential Fitness, Northfield Bancorp
Ovid hits record low as developer Takeda says seizure drug fails
U.S. STOCKS ON THE MOVE-Autodesk, Aaron's Company
Ovid Therapeutics plummets after Takeda's drug fails in late-stage studies
Brief: Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
Takeda's seizure drug fails to meet main goal in late-stage studies (updated)
Ovid Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Ovid Therapeutics Q1 EPS USD -0.17 Vs. IBES Estimate USD -0.22
Ovid Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Domino's Pizza, HCA Healthcare, HCA Healthcare
Ovid Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Ovid Therapeutics Q4 EPS USD -0.22 Vs. IBES Estimate USD -0.05
Ovid Therapeutics Inc expected to post a loss of 5 cents a share - Earnings Preview
Ovid Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Ovid Therapeutics Q3 EPS USD -0.16